(Information sent by the signatory company)
SINGAPORE, Dec. 16, 2022/PRNewswire/ -- Neuome Peptides Pte. Ltd., a Singapore-based company, has created an assay development platform based on machine learning and novel proprietary algorithms for quantifiable biomarker detection .
The company has successfully engineered specific peptides that bind to pre-established and proven biomarkers of cardiovascular disease, and is currently developing effective diagnostic assays. The use of small peptides, conjugated with gold nanoparticles, allows a balance of high specificity and sensitivity, giving very precise and fast results.
According to the European Heart Network, cardiovascular diseases cause 3.9 million deaths each year in Europe and more than 1.8 million in the European Union.
This is made possible by the TruHeart™ product, a point-of-care acute coronary syndrome assay that can provide measurable results in 3-5 minutes, using a fingerstick sample to test for the crucial biomarkers, troponins I and T. , and myoglobin (will eventually expand to D-dimer and brain natriuretic peptide). It is in an advanced stage of R&D and moving towards global clinical trials. After its approval by the FDA, it will be introduced to the market.
This product could be a game changer, allowing patients to affordably and early detect this life-threatening disease in their own home and obtain measurable results without the need to visit a laboratory. In this way, patients are more effectively guided to seek appropriate medical care; Those with prevalent heart conditions will also be able to regularly monitor their condition at home. Compared to industry standards, it will be exceptionally affordable; their peptide-coated cartridges will cost only ~$2, while the quantitative e-reader will cost ~$80. This is in contrast to existing point-of-care devices, which also offer quantitative cardiac biomarker results, but priced as low as $4,500 and with cartridges ranging from $18 to $37.
The company's Scientific Advisory Board includes prominent leaders in the field, such as Padmashri Balram Bhargava, former Director General of the Indian Council of Medical Research (ICMR). The company has scheduled clinical trials at five hospitals in India (including the renowned NarayanaHrudayalaya), in the process of securing a large US site and five sites in Europe. It is also in advanced discussions with A*Star and the National Heart Center of Singapore. This is just one of many products in development made possible by his proprietary method of peptide design. The immediate portfolio of products includes assays for prostate and colorectal cancers, dengue fever, and malaria, among others.
About Neuome Peptides
He specializes in using a peptide-based approach to disrupt and democratize the diagnostics industry with affordable devices, capable of delivering lab-quality results in a fraction of the time and at a fraction of the cost. In line with its motto, "Convergence of Science", it integrates elements of life sciences, nanotechnology, electronics and AI/machine learning into its products. The company is aware of the cost inefficiencies of existing diagnostic solutions, so its mission is to develop accurate, efficient and affordable diagnostic solutions for prevalent global health problems.
Learn more about TruHeart™: https://neuomepeptides.com/truheart/
Photo - https://mma.prnewswire.com/media/1968350/TruHeart_04.jpg
Logo - https://mma.prnewswire.com/media/1968342/NeuomePeptides_newLogo__1_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/posible-avance-en-el-diagnostico-de-enfermedades-cardiovasculares-para-europa-y-la-union-europea-301705431.html
